Amneal Pharmaceuticals Inc (NYSE:AMRX) disclosed on Friday the receipt of the US FDA approval for the generic version of BiCNU (carmustine) for injection in 100 mg.
In conjunction, the company plans to launch its Carmustine for Injection in November 2018. Carmustine is a medication used mainly for chemotherapy.
For the 12 months ended August 2018, the US market annual sales for Carmustine for Injection USP in 100 mg/vial is estimated to be about USD84m, according to IQVIA.
Headquartered in Bridgewater, NJ, the specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.
DifGen Pharmaceuticals' Fluorometholone Ophthalmic Suspension, 0.1% receives FDA approval
Viatris names new chief legal officer
Alvotech signs biosimilar supply and commercialisation deals with Sandoz
InSysBio agrees new collaborative project with BeOne Medicines
Apiject to open new generic injectable drug manufacturing facility in Apex, NC
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Accord Healthcare launches Clomiphene tablets in US market
Zentiva receives ESG Transparency Award 2025
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval